The licensing of medications for use in pregnancy represents a double edged sword in need of urgent attention. While product licences are important in instilling some sense of confidence that a medication meets stringent tests of efficacy and safety in the management of a specific condition in a specific population, they remain subject to significant limitations and biases. Given the commercial nature of the pharmaceutical industry, many would consider that product licensing is not just solely reflective of a medication passing a regulatory benefit-risk analysis, but also a more stringent internal profit-loss analysis.
|Number of pages||2|
|Journal||European Journal of Obstetrics and Gynecology and Reproductive Biology|
|Publication status||Published - Apr 2015|
- medications during pregnancy
- medico-legal concerns